Savara is a clinical-stage biopharmaceutical company developing therapies for rare respiratory diseases. Its lead programme, molgramostim (an inhaled form of GM-CSF), targets autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disorder in which surfactant builds up in the alveoli. The company focuses on underserved pulmonary niches where specialised inhaled biologics may address disease biology more directly than systemic treatments.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -30.4 | — |
| Q3 2025 | 0 | — | -29.6 | — |
| Q4 2025 | 0 | — | -32.2 | — |
| Q1 2026 | 0 | — | -37.3 | — |
| Q2 2026 | 0 | — | -40.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Bumble Inc. (BMBL), Bioventus Inc. (BVS), Farmers National Banc Corp. (FMNB), Sinclair, Inc. (SBGI), American Public Education, Inc. (APEI), Willis Lease Finance Corporation (WLFC)